Kraan W - Search Results

1

Ibrutinib and idelalisib target B cell receptor- but not CXCL12/CXCR4-controlled integrin-mediated adhesion in Waldenström macroglobulinemia.

de Rooij MF, Kuil A, Kraan W, Kersten MJ, Treon SP, Pals ST, Spaargaren M. de Rooij MF, et al. Among authors: kraan w. Haematologica. 2016 Mar;101(3):e111-5. doi: 10.3324/haematol.2015.137265. Epub 2015 Dec 3. Haematologica. 2016. PMID: 26635033 Free PMC article. No abstract available.

2

MYD88 mutations identify a molecular subgroup of diffuse large B-cell lymphoma with an unfavorable prognosis.

Vermaat JS, Somers SF, de Wreede LC, Kraan W, de Groen RAL, Schrader AMR, Kerver ED, Scheepstra CG, Berenschot H, Deenik W, Wegman J, Broers R, de Boer JD, Nijland M, van Wezel T, Veelken H, Spaargaren M, Cleven AH, Kersten MJ, Pals ST. Vermaat JS, et al. Among authors: kraan w. Haematologica. 2020 Jan 31;105(2):424-434. doi: 10.3324/haematol.2018.214122. Print 2020. Haematologica. 2020. PMID: 31123031 Free PMC article.

3

The CXCL12gamma chemokine immobilized by heparan sulfate on stromal niche cells controls adhesion and mediates drug resistance in multiple myeloma.

Ren Z, Lantermans H, Kuil A, Kraan W, Arenzana-Seisdedos F, Kersten MJ, Spaargaren M, Pals ST. Ren Z, et al. Among authors: kraan w. J Hematol Oncol. 2021 Jan 12;14(1):11. doi: 10.1186/s13045-021-01031-3. J Hematol Oncol. 2021. PMID: 33436043 Free PMC article.

4

Discriminating between Waldenström macroglobulinemia and marginal zone lymphoma using logistic LASSO regression.

Amaador K, Vos JMI, Pals ST, Kraan W, Dobber JA, Minnema MC, Koene HR, de Bruin PC, Zwinderman AH, Kersten MJ. Amaador K, et al. Among authors: kraan w. Leuk Lymphoma. 2022 May;63(5):1070-1079. doi: 10.1080/10428194.2021.2018584. Epub 2021 Dec 27. Leuk Lymphoma. 2022. PMID: 34961399

5

Correction to: The CXCL12gamma chemokine immobilized by heparan sulfate on stromal niche cells controls adhesion and mediates drug resistance in multiple myeloma.

Ren Z, Lantermans H, Kuil A, Kraan W, Arenzana-Seisdedos F, Kersten MJ, Spaargaren M, Pals ST. Ren Z, et al. Among authors: kraan w. J Hematol Oncol. 2021 Feb 16;14(1):29. doi: 10.1186/s13045-021-01038-w. J Hematol Oncol. 2021. PMID: 33593389 Free PMC article. No abstract available.

6

Immune evasion in primary testicular and central nervous system lymphomas: HLA loss rather than 9p24.1/PD-L1/PD-L2 alterations.

Minderman M, Amir A, Kraan W, Schilder-Tol EJM, Oud MECM, Scheepstra CG, Noorduyn AL, Kluin PM, Kersten MJ, Spaargaren M, Pals ST. Minderman M, et al. Among authors: kraan w. Blood. 2021 Sep 30;138(13):1194-1197. doi: 10.1182/blood.2021011366. Blood. 2021. PMID: 34125179 Free PMC article. No abstract available.

7

Combining Ixazomib With Subcutaneous Rituximab and Dexamethasone in Relapsed or Refractory Waldenström's Macroglobulinemia: Final Analysis of the Phase I/II HOVON124/ECWM-R2 Study.

Kersten MJ, Amaador K, Minnema MC, Vos JMI, Nasserinejad K, Kap M, Kastritis E, Gavriatopoulou M, Kraan W, Chamuleau MED, Deeren D, Tick LW, Doorduijn JK, Offner F, Böhmer LH, Liu RD, Pals ST, Dimopoulos MA. Kersten MJ, et al. Among authors: kraan w. J Clin Oncol. 2022 Jan 1;40(1):40-51. doi: 10.1200/JCO.21.00105. Epub 2021 Aug 13. J Clin Oncol. 2022. PMID: 34388022 Free PMC article. Clinical Trial.

8

High prevalence of oncogenic MYD88 and CD79B mutations in primary testicular diffuse large B-cell lymphoma.

Kraan W, van Keimpema M, Horlings HM, Schilder-Tol EJ, Oud ME, Noorduyn LA, Kluin PM, Kersten MJ, Spaargaren M, Pals ST. Kraan W, et al. Leukemia. 2014 Mar;28(3):719-20. doi: 10.1038/leu.2013.348. Epub 2013 Nov 20. Leukemia. 2014. PMID: 24253023 No abstract available.

9

Diffuse large B cell lymphomas relapsing in the CNS lack oncogenic MYD88 and CD79B mutations.

Kersten MJ, Kraan W, Doorduijn J, Bromberg J, Lam K, Kluin PM, van der Holt BJ, Spaargaren M, Pals ST. Kersten MJ, et al. Among authors: kraan w. Blood Cancer J. 2014 Dec 12;4(12):e266. doi: 10.1038/bcj.2014.87. Blood Cancer J. 2014. PMID: 25501023 Free PMC article. Clinical Trial. No abstract available.

10

High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sites.

Kraan W, Horlings HM, van Keimpema M, Schilder-Tol EJ, Oud ME, Scheepstra C, Kluin PM, Kersten MJ, Spaargaren M, Pals ST. Kraan W, et al. Blood Cancer J. 2013 Sep 6;3(9):e139. doi: 10.1038/bcj.2013.28. Blood Cancer J. 2013. PMID: 24013661 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

21 results

Search Page

Filters